Rational Design of CRISPR/Cas9-engineered TIL Therapies
Time: 11:30 am
day: Day Two
Details:
• Harnessing CRISPR to identify TIL-enhancing targets
• Analyzing designing and manufacturing next-gen TIL therapies with increased anti-tumor potency
• Examining KSQ-001 and KSQ-004 as single- and dual-edited CRISPR/Cas9- engineered TIL products
